Methods to Improve Adoptive T-Cell Therapy for Melanoma: IFN-γ Enhances Anticancer Responses of Cell Products for Infusion

Keyphrases

• Melanoma 100%
• Tumor-infiltrating Lymphocytes 100%
• Anticancer Response 100%
• Adoptive Cell Therapy 100%
• Cellular Products 100%
• Metastatic Melanoma 66%
• Clinical Response 33%
• Clinical Development 33%
• Clinical Efficacy 33%
• Long-term Prognosis 33%
• Melanoma Cells 33%
• Tumor Antigen 33%
• CD4+ T Cells 33%
• Adoptive Transfer 33%
• Further Development 33%
• CD-8 33%
• Synergism 33%
• Antitumor 33%
• Autologous Tumors 33%
• Enhanced Response 33%
• Combination Strategy 33%
• Tumor Reactivity 33%
• Tumor Immunogenicity 33%
• Differentiation Antigen 33%
• Major Histocompatibility Complex Molecules 33%

Medicine and Dentistry

• Infusion 100%
• T Cell 100%
• Nodular Melanoma 100%
• Tumor Infiltrating Lymphocyte 100%
• Cell Therapy 100%
• Metastatic Melanoma 66%
• Malignant Neoplasm 33%
• Neoplasm 33%
• Major Histocompatibility Complex 33%
• In Vitro 33%
• Upregulation 33%
• Sensitization 33%
• Low Drug Dose 33%
• T-Helper Cell 33%
• Cytotoxic T-Cell 33%
• Melanoma Cell Line 33%
• Adoptive Transfer 33%
• Immunogenicity 33%
• Tumor Antigen 33%
• Differentiation Antigen 33%

Biochemistry, Genetics and Molecular Biology

• T Cell 100%
• Anticancer 100%
• Tumor-Infiltrating Lymphocytes 75%
• Major Histocompatibility Complex 25%
• Low Drug Dose 25%
• Upregulation 25%
• Sensitization 25%
• CD8 25%
• CD4 25%
• Immunogenicity 25%
• Tumor Antigen 25%